Home › Research › Down syndrome and Alzheimer's
The Genetics and Mechanisms of Alzheimer's Disease in Down Syndrome
Michel Bourin. Journal of Mental Health Disorders, 2026-04-18
Topic: Amyloid, tau and blood-test diagnosis
Down syndrome (DS), caused by trisomy 21, is the most frequent genetic cause of intellectual disability worldwide. Advances in medical care have markedly increased life expectancy, revealing a new clinical challenge: premature aging and a very high prevalence of Alzheimer’s disease (AD) in adulthood. Nearly all adults with DS develop cerebral amyloid pathology by midlife, largely due to overexpression of the amyloid precursor protein gene located on chromosome 21. However, the onset and severity of dementia vary considerably, suggesting the involvement of additional genetic, cellular, and environmental modifiers. This narrative review examines the molecular and cellular mechanisms underlying early brain aging in DS, with particular emphasis on Alzheimer-type neurodegeneration. We discuss gene dosage effects and candidate genes implicated in synaptic dysfunction, endo-lysosomal abnormalities as early cellular biomarkers, clinical and neuropsychological challenges in diagnosing dementia in individuals with DS, and recent advances linking gonadotropin-releasing hormone (GnRH) dysfunction to cognitive impairment. Experimental and preliminary clinical evidence suggests that restoration of physiological GnRH signaling may improve cognition and functional brain connectivity in adults with DS. Understanding DS as a genetically determined form of Alzheimer’s disease offers a unique opportunity to identify early biomarkers and develop preventive or disease-modifying therapies relevant not only to DS but also to sporadic neurodegenerative disorders.
Key findings
- Experimental and preliminary clinical evidence suggests that restoration of physiological GnRH signaling may improve cognition and functional brain connectivity in adults with DS.
Why it matters
This review discusses how nearly all adults with Down syndrome develop amyloid pathology by midlife, and that experimental and preliminary clinical evidence suggests restoring gonadotropin-releasing hormone signaling may improve cognition. This is early evidence and not yet a proven treatment.
Study details
- Study designnarrative review
- Evidence strengthLow
How this study scored 26/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Mental Health Disorders) |
| Journal's citation record | 0 / 4 | Journal of Mental Health Disorders: journal h-index 3 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author Michel Bourin: h-index 1 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Nantes Université: institution h-index 564 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 26 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.33696/mentalhealth.6.069
- Original source →
- Free full text: Journal of Mental Health Disorders →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Bourin, M. (2026). The Genetics and Mechanisms of Alzheimer's Disease in Down Syndrome. Journal of Mental Health Disorders. https://doi.org/10.33696/mentalhealth.6.069
Vancouver
Bourin M. The Genetics and Mechanisms of Alzheimer's Disease in Down Syndrome. Journal of Mental Health Disorders. 2026. doi:10.33696/mentalhealth.6.069.
BibTeX
@article{bourin2026-5d481cbc,
author = {Bourin, Michel},
title = {{The Genetics and Mechanisms of Alzheimer's Disease in Down Syndrome}},
journal = {Journal of Mental Health Disorders},
year = {2026},
doi = {10.33696/mentalhealth.6.069},
url = {https://doi.org/10.33696/mentalhealth.6.069}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Down syndrome and Alzheimer's
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.